@article {Izquierdo2020.07.24.20161596, author = {Jos{\'e} Luis Izquierdo and Carlos Almonacid and Yolanda Gonz{\'a}lez and Carlos Del Rio-Berm{\'u}dez and Julio Ancochea and Remedios C{\'a}rdenas and Joan B Soriano}, title = {The impact of COVID-19 on patients with asthma}, elocation-id = {2020.07.24.20161596}, year = {2020}, doi = {10.1101/2020.07.24.20161596}, publisher = {Cold Spring Harbor Laboratory Press}, abstract = {Background From the onset of the COVID-19 pandemic, an association between the severity of COVID-19 and the presence of certain medical chronic conditions has been suggested. However, unlike influenza and other viruses, the burden of the disease in patients with asthma has been less evident.Objective This study aims at a better understanding of the burden of COVID-19 in patients with asthma and the impact of asthma, its related comorbidities, and treatment on the prognosis of COVID-19.Methods We analyzed clinical data from patients with asthma from January 1st to May 10th, 2020 using big data analytics and artificial intelligence through the SAVANA Manager{\textregistered} clinical platform.Results Out of 71,192 patients with asthma, 1,006 (1.41\%) suffered from COVID-19. Compared to asthmatic individuals without COVID-19, patients with asthma and COVID-19 were significantly older (55 vs. 42 years), predominantly female (66\% vs. 59\%), had higher prevalence of hypertension, dyslipidemias, diabetes, and obesity, and smoked more frequently. Contrarily, allergy-related factors such as rhinitis and eczema were less frequent in asthmatic patients with COVID-19 (P \< .001). Higher prevalence of hypertension, dyslipidemia, diabetes, and obesity was also confirmed in those patients with asthma and COVID-19 who required hospital admission. The percentage of individuals using inhaled corticosteroids (ICS) was lower in patients who required hospitalization due to COVID-19, as compared to non-hospitalized patients (48.3\% vs. 61.5\%; OR: 0.58: 95\% CI 0.44 - 0.77). During the study period, 865 (1.21\%) patients with asthma were being treated with biologics. Although these patients showed increased severity and more comorbidities at the ear, nose, and throat (ENT) level, their hospital admission rates due to COVID-19 were relatively low (0.23\%). COVID-19 increased inpatient mortality in asthmatic patients (2.29\% vs 0.54\%; OR 2.29: 95\% CI 4.35 {\textendash} 6.66).Conclusion Our results indicate that the number of COVID-19 cases in patients with asthma has been low, although higher than the observed in the general population. Patients with asthma and COVID-19 were older and were at increased risk due to comorbidity-related factors. ICS and biologics are generally safe and may be associated with a protective effect against severe COVID-19 infection.Competing Interest StatementThe authors have declared no competing interest.Funding StatementGrant COVID-19 UAH 2019/00003/016/001/005 from the University of Alcala (Spain).Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:The study was conducted in accordance with legal and regulatory requirements and followed research practices described in the ICH Guidelines for Good Clinical Practice, the Declaration of Helsinki in its latest edition, the Guidelines for Good Pharmacoepidemiology Practice (GPP), and local regulations. Given the retrospective and observational nature of the study, physicians{\textquoteright} prescribing habits and patient assignment to a specific therapeutic strategy were solely determined by the physician, team, or hospital concerned. Likewise, a standard informed consent does not apply to this study. All actions towards data protection were taken in accordance with the European Data Protection authorities{\textquoteright} code of good practice regarding big data projects and the European General Data Protection Regulation (GDPR). This study was approved by the Ethics and Research Committee of the University Hospital of Guadalajara (Spain).All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesData not publicly available due to legal restrictions}, URL = {https://www.medrxiv.org/content/early/2020/07/28/2020.07.24.20161596}, eprint = {https://www.medrxiv.org/content/early/2020/07/28/2020.07.24.20161596.full.pdf}, journal = {medRxiv} }